Lupin eyes acquisitions in various global markets

29 Dec 2014 Evaluate

In a bid to bolster its presence overseas, drug major Lupin is eyeing acquisitions in various global markets, including the US, Latin America and Europe. The company, which has already entered the Mexican market, would also continue to look for acquisitions in key Latam markets such as Brazil.

During the last fiscal, global markets (excluding India) accounted for around 75 per cent of the company’s total revenues, which stood over Rs 11,000 crore.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin Share Price

1661.90 0.00 (0.00%)
18-May-2024 12:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1532.85
Dr. Reddys Lab 5812.50
Cipla 1403.90
Zydus Lifesciences 1104.45
Lupin 1661.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.